Brief: Transcode Therapeutics Announces IND Submission To FDA For Advanced Solid Tumors Drug Study
30/11/2022 12:31
Nov 30 (Reuters) - Transcode Therapeutics Inc RNAZ.O :
* TRANSCODE THERAPEUTICS ANNOUNCES EIND SUBMISSION TO US FDA
FOR
PLANNED FIRST-IN-HUMAN CLINICAL TRIAL IN PATIENTS WITH ADVANCED
SOLID TUMORS
Source text for Eikon: ID:nGNX8PvQfT
Further company coverage: RNAZ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Transcode Therapeutics
See all newsBrief: TransCode Therapeutics Appoints John Tattory As Interim CFO
Brief: Transcode Therapeutics Appoints Dr. Anna Moore As Chair Of Scientific Advisory Board
Brief: Transcode Therapeutics Inc - Enters Exclusive License Agreement With Unleash
Brief: Transcode Therapeutics Ttx-Mc138 Phase 2A Clinical Trial Expected In First Half Of 2026
Brief: Transcode Therapeutics Expands Leadership With Appointment Of Jack E. Stover To Board Of Directors